News

The company has been developing BB3, which is a proprietary small molecule that mimics the activity of hepatocyte growth factor (HGF). In preclinical models of AKI, BB3 showed

Earlier, the company had announced plans to submit the multi-center, randomized Phase II trial completed last year as one of two pivotal trials required for a new drug

EMDAC voted 13 to 3 that the companies had sufficiently established that the low-density lipoprotein cholesterol (LDL-C) lowering benefit of Praluent exceeds its risks to support approval in

The second successfully out-licensed biosimilar in the product pipeline is ABY-021, which is a humanized monoclonal antibody for treating immunological symptoms. The out-licensing partner is once again a

Advantar’s manufacturing suite includes an ingress/egress area, weighing and dispensing area and equipment clean up area. The manufacturing area and ingress/egress areas are ISO 8 (Class 100,000), HEPA-filtered

Two of these medicines are for the treatment of psoriasis and a third has been accepted for psoriatic arthritis. The other new medicines accepted are the latest of

The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in

The alliance will try to identify, assess and work on fertility-related laboratory processes, co-ordinate to improve consistency in ART worldwide and is likely to be a solution for

eHealthStore was created through CPM’s strategic alliance with Retailigence, a leading platform connecting marketers with a nationwide shopper audience on the path-to-purchase. Through this new development, CPM now